iCell Therapeutics To Present At Invest Northwest 2005, April 27

VANCOUVER, British Columbia, April 22 /PRNewswire/ -- Kito Tosetti, CEO of iCell Therapeutics (http://www.icelltherapeutics.com/), will present at the Washington Biotechnology & Biomedical Association's (WBBA) Invest Northwest, a life sciences and CEO investor conference on Wednesday, April 27, 2005. Mr. Tosetti will provide a corporate overview, along with highlights from the Company's smart targeted chemotherapies, and the results of the human safety studies.

Presentation details are as follows: What: Invest Northwest 2005 Conference Where: Seattle, WA Bell Harbor Conference Center, Pacific Boardroom When: Wednesday, April 27, 2005 at 11:00 AM PDT

iCell Therapeutics Inc. develops smart targeted treatments to address the unmet needs of certain types of cancer and cardiovascular diseases such as restenosis, aneurisms, and atherosclerosis. iCell Therapeutics' site selective platform technology is validated by its successful phase I clinical trials results and an extensive series of pre-clinical studies.

Company's successful achievement of all key milestones planned in its 2004 research and development program has created the foundations to its methodological progress towards worldwide commercialization of its targeted chemotherapies and set the ground floor opportunity for a high value investment.

CONTACT: Kito Tosetti, CEO or Ali Ardakani, Director of CorporateDevelopment, both of iCell Therapeutics Inc., +1-604-922-3827, orinfo@icelltherapeutics.com

Web site: http://www.icelltherapeutics.com/